期刊文献+

miR-182调控RECK信号通路在非小细胞肺癌进展中的作用 被引量:11

Effect of mi R-182 in non small cell lung cancer via regulating the RECK signaling pathway
下载PDF
导出
摘要 目的探讨miR-182在非小细胞肺癌(NSCLC)发展中的作用及其相关机制。方法采用实时定量PCR检测NSCLC细胞系以及30组配对的NSCLC患者癌组织和癌旁组织样本中miR-182的表达水平。在NSCLC细胞株A549和H1299中过表达miR-182后,测定细胞增殖活性及侵袭转移能力。利用荧光素酶活性实验鉴定miR-182的预测靶基因(RECK)。采用qRT-PCR和Western blotting分别检测转染miR-182类似物和miR-182抑制物后RECK mRNA和蛋白的表达水平。结果miR-182在NSCLC细胞系和癌组织中的表达水平明显高于癌旁组织,在伴淋巴结转移的肺癌患者癌组织中的表达水平明显高于不伴淋巴结转移者,差异有统计学意义(P<0.01)。过表达miR-182可增强NSCLC细胞株A549和H1299的增殖、侵袭和迁移能力。双荧光素酶实验结果表明,RECK的翻译水平受miR-182直接调控。qRT-PCR和Western blotting 检测结果表明,转染miR-182类似物后,RECK表达水平降低,转染miR-182抑制物后,RECK表达水平升高。结论miR-182可调控RECK的表达,促进NSCLC的进展。 Objective To explore the effect of mi R-182 in non small cell lung cancer(NSCLC) and its mechanism. Methods The expression level and difference of mi R-182 were detected by q RT-PCR in NSCLC cell line and matched tissues of 30 patients suffering from NSCLC. Cell proliferation, invasion and metastasis of A549 and H1299 via mi R-182 was detected by mi R-182 mimics. The predicted target gene(RECK) of mi R-182 was identified via luciferase activation assay. The mRNA or protein expression of RECK after mi R-182 mimic or inhibitor transfection was detected by q RT-PCR or Western blotting, respectively. Results Expression of mi R-182 was significantly increased in NSCLC tissues and cell lines compared with that in the adjacent tissues(P〈0.01), and it was correlated with the metastasis of NSCLC. The cell proliferation, invasion, and migration capacity was increased after mi R-182 mimics transfection. Dual luciferase assay showed that mi R-182 directly regulated the RECK translation level. RECK expression level was decreased after mi R-182 mimics transfection in the A549 cells, while increased after mi R-182 inhibitor transfection. Conclusion mi R-182 promoted tumor growth and metastasis of NSCLC by down-regulating the RECK expression.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2015年第4期309-314,共6页 Medical Journal of Chinese People's Liberation Army
基金 重庆市科委重点攻关课题(CSTC2011AB5032)~~
关键词 非小细胞肺 微RNAS 基因 RECK carcinoma, non-small-cell lung microRNAs genes, RECK
  • 相关文献

参考文献6

二级参考文献66

  • 1罗扬,冯奉仪,要洁,张湘茹,王绿化,张德超.231例非小细胞肺癌术后生存和预后分析[J].中国肿瘤临床,2005,32(2):92-94. 被引量:11
  • 2Yuh YJ, Lee HR, Kim SR, et al. Gemcitabine and carboplatin combination chemotherapy for elderly patient with advanced non-small lung cancer: A feasibility study [J]. Cancer Res Treat, 2008, 40(3):116-120.
  • 3Yu Y, Xu X, Du Z, et al. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta- analysis on 9 randomized controlled trials[J]. Cancer Chemother Pharmacol, 2012, 69(5): 1265-1275.
  • 4Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non- small-cell lung cancer: a phase Ⅲ randomized trial [J]. J Clin Oncol, 2005, 23(13):2940-2942.
  • 5Baykara M, Coskun U, Berk V, et al. Gemcitabine plus paclitaxel as second-line chemotherapy in patient with advanced non-Small cell cancer[J]. Asian Pac J Cancer Prev, 2012, 13(10):5119- 5121.
  • 6Jiang J, Liang X, Zhou X, et al. PacIitaxeI plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials[J]. IntJ Clin Oncol, 2012, Epub ahead of print.
  • 7Minami S, Kijima T, Shiroyama T, et al. Randomized phase Ⅱ trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer[J]. BMC Res Notes, 2013, 6(1): 3.
  • 8Lv C, based Ma Y, induc Wu N, et al. A retrospective study: platinum chemo or paclitaxel for stage therapy combined with gemcitabine Ⅱ B- ⅢA central non-small-cell lung cancer[J]. World J Surg Oncol, 2013, 11:76.
  • 9Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel [J]. J Clin Oncol, 2005, 23( 13): 3125-3137.
  • 10Mountain CF. Revisions in the international system for staging lung cancer[J]. Chest, 1997, 111(6): 1710-1717.

共引文献58

同被引文献132

引证文献11

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部